A network-based analysis of key pharmacological pathways of Corilagin acting on Breast cancer and experimental validation
Zhong Xue, Tang Jintian, Long Wenyue and 3 more
E3S Web of Conferences · 2020
doi:10.1051/e3sconf/202018502004 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
The combination of network pharmacological methods and experimental verification has revealed the underlying molecular mechanism of Corilagin in the treatment of breast cancer. In this study, we used Swiss Target Prediction database network to predict the possible candidate targets and pathways of Coilagin, and collect breast cancer targets and pathways of CooLGeN. The result of network pharmacological screen indicated that Bcl is a key pathway for Corilagin in the treatment of breast cancer. The CCK-8 experiment also proved that Corilagin could inhibit the proliferation of MCF-7 cells. Western Blot was used for the validation of network pharmacological results, which showed that Corilagin could increase the apoptosis rates (Bcl-2/Bax) of MCF-7 cells, and up-regulates the apoptotic protein Caspase-3 and changes the Bcl-2 family proteins expression in MCF-7 cells. All results suggest that Corilagin has the potential therapeutic effects on breast cancer, and may be useful for adjuvant chemotherapy.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.